Skip to main content
PMC home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2010 Mar 1;78(6):531–540. doi: 10.1016/S1081-1206(10)63213-9

Epidemiology, Pathogenesis, and Treatment of the Common Cold

Ronald B Turner 1,**
PMCID: PMC7128171  PMID: 9207716

Abstract

Objective

Reading this article will reinforce the reader's knowledge of the pathogenesis of the common cold. The rationale for current and potential therapies for the common cold are reviewed in the context of current concepts of the pathogenesis of these illnesses.

Data sources and study selection

A MEDLINE literature search was done using the search terms common cold, rhinovirus, and viral respiratory infection. The search was restricted to the English language. Articles were selected for review if the title and/or abstract suggested the content was relevant to the subject of this review. The bibliographies of selected articles were used as a source of additional literature.

Results

Recent studies suggest that the host response to the virus is an important contributor to the pathogenesis of the common cold. Inflammatory mediators, especially the pro-inflammatory cytokines, appear to be an important component of this response and present an attractive target for new interventions for common cold therapies. Currently available treatments for the common cold have limited efficacy against specific symptoms. These therapies should be selected to treat the specific symptoms that are perceived to be the most bothersome by the patient.

Footnotes

Supported by a grant from Zeneca Pharmaceuticals

References

  • 1.Dingle JH, Badger GF, Jordan WS., Jr . Illness in the home: a study of 25,000 illnesses in a group of Cleveland families. Case Western Reserve University Press; Cleveland: 1964. pp. 33–96. [Google Scholar]
  • 2.Gwaltney JM, Jr, Hendley JO, Simon G, Jordan WS., Jr Rhinovirus infections in an industrial population. I. The occurrence of illness. N Engl J Med. 1966;275:1261–1268. doi: 10.1056/NEJM196612082752301. [DOI] [PubMed] [Google Scholar]
  • 3.HHS: Vital Health Statistics 10. Washington, D.C., 1986.
  • 4.Rosenthal I. Expense of physician care spurs OTC, self-care market. Drug Topics. 1988;132:62–63. [Google Scholar]
  • 5.Kogan MD, Pappas G, Yu SM, Kotelchuck M. Over-the-counter medication use among US preschool-age children. JAMA. 1994;272:1025–1030. [PubMed] [Google Scholar]
  • 6.Monto AS, Cavallaro JJ. The Tecumseh study of respiratory illness. II. Patterns of occurrence of infection with respiratory pathogens, 1965–1969. Am J Epidemiol. 1971;94:280–289. doi: 10.1093/oxfordjournals.aje.a121321. [DOI] [PubMed] [Google Scholar]
  • 7.Johnston SL, Pattemore PK, Sanderson G. The relationship between upper respiratory infections and hospital admissions for asthma: a timetrend analysis. Am J Respir Crit Care Med. 1996;154:654–660. doi: 10.1164/ajrccm.154.3.8810601. [DOI] [PubMed] [Google Scholar]
  • 8.Tyrrell DA, Cohen S, Schlarb JE. Signs and symptoms in common colds. Epidemiol Infect. 1993;111:143–156. doi: 10.1017/s0950268800056764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Harris JM, II, Gwaltney JM., Jr Incubation periods of experimental rhinovirus infection and illness. J Infect Dis. 1996;23:1287–1290. doi: 10.1093/clinids/23.6.1287. [DOI] [PubMed] [Google Scholar]
  • 10.Gwaltney JM, Jr, Hendley JO, Simon G, Jordan WS., Jr Rhinovirus infections in an industrial population. II. Characteristics of illness and antibody response. JAMA. 1967;202:494–500. [PubMed] [Google Scholar]
  • 11.Turner RB, Witek TJ, Jr, Riker DK. Comparison of symptom severity in natural and experimentally induced colds. Am J Rhinol. 1996;10:167–172. [Google Scholar]
  • 12.Frank AL, Taber LH, Wells CR. Patterns of shedding myxoviruses and paramyxoviruses in children. J Infect Dis. 1981;144:433–441. doi: 10.1093/infdis/144.5.433. [DOI] [PubMed] [Google Scholar]
  • 13.Winther B, Gwaltney JM, Jr, Mygind N. Sites of rhinovirus recovery after point inoculation of the upper airway. JAMA. 1986;256:1763–1767. [PubMed] [Google Scholar]
  • 14.Monto AS, Ullman BM. Acute respiratory illness in an American community: the Tecumseh study. JAMA. 1974;227:164–169. [PubMed] [Google Scholar]
  • 15.Monto AS, Sullivan KM. Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol Infect. 1993;110:145–160. doi: 10.1017/s0950268800050779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Wald ER, Dashefshy B, Byers C. Frequency and severity of infections in day care. J Pediatr. 1988;112:540–546. doi: 10.1016/s0022-3476(88)80164-1. [DOI] [PubMed] [Google Scholar]
  • 17.Hurwitz ES, Gunn WJ, Pinsky PF, Schonberger LB. Risk of respiratory illness associated with daycare attendance: a nationwide study. Pediatr. 1991;87:62–69. [PubMed] [Google Scholar]
  • 18.Fleming DW, Cochi SL, Hightower AW, Broome CV. Childhood upper respiratory tract infections: to what degree is incidence affected by daycare attendance. Pediatr. 1987;79:55–60. [PubMed] [Google Scholar]
  • 19.D'Alessio DJ, Peterson JA, Dick CR, Dick EC. Transmission of experimental rhinovirus colds in volunteer married couples. J Infect Dis. 1976;133:28–36. doi: 10.1093/infdis/133.1.28. [DOI] [PubMed] [Google Scholar]
  • 20.Meschievitz CK, Schultz SB, Dick EC. A model for obtaining predictable natural transmission of rhinoviruses in human volunteers. J Infect Dis. 1984;150:195–201. doi: 10.1093/infdis/150.2.195. [DOI] [PubMed] [Google Scholar]
  • 21.D'Alessio DJ, Meschievitz CK, Peterson JA. Short-duration exposure and the transmission of rhino-viral colds. J Infect Dis. 1984;150:189–194. doi: 10.1093/infdis/150.2.189. [DOI] [PubMed] [Google Scholar]
  • 22.Dick EC, Jennings LC, Mink KA. Aerosol transmission of rhinovirus colds. J Infect Dis. 1987;156:442–448. doi: 10.1093/infdis/156.3.442. [DOI] [PubMed] [Google Scholar]
  • 23.Gwaltney JM, Jr, Moskalski PB, Hendley JO. Hand-to-hand transmission of rhinovirus colds. Ann Intern Med. 1978;88:463–467. doi: 10.7326/0003-4819-88-4-463. [DOI] [PubMed] [Google Scholar]
  • 24.Hendley JO, Gwaltney JM., Jr Mechanisms of transmission of rhinovirus infections. Epidemiol Rev. 1988;10:243–258. [PubMed] [Google Scholar]
  • 25.Hall CB, Douglas RG., Jr Modes of transmission of respiratory syncytial virus. J Pediatr. 1981;99:100–103. doi: 10.1016/s0022-3476(81)80969-9. [DOI] [PubMed] [Google Scholar]
  • 26.Douglas RG., Jr . Influenza in man. In: Kilbourne ED, editor. The influenza viruses and influenza. Academic Press; New York: 1975. pp. 385–447. [Google Scholar]
  • 27.Moser MR, Bender TR, Margolis HS. An outbreak of influenza aboard a commercial airliner. Am J Epidemiol. 1979;110:1–6. doi: 10.1093/oxfordjournals.aje.a112781. [DOI] [PubMed] [Google Scholar]
  • 28.Hendley JO, Edmonson WP, Jr, Gwaltney JM., Jr Relation between naturally acquired immunity and infectivity of two rhinoviruses in volunteers. J Infect Dis. 1972;125:243–248. doi: 10.1093/infdis/125.3.243. [DOI] [PubMed] [Google Scholar]
  • 29.Hendley JO, Wenzel RP, Gwaltney JM., Jr Transmission of rhinovirus colds by self-inoculation. N Engl J Med. 1973;288:1361–1364. doi: 10.1056/NEJM197306282882601. [DOI] [PubMed] [Google Scholar]
  • 30.Turner RB, Winther B, Hendley JO. Sites of virus recovery and antigen detection in epithelial cells during experimental rhinovirus infection. Acta Otolaryngol (Suppl) 1984;413:9–14. doi: 10.3109/00016488409128535. [DOI] [PubMed] [Google Scholar]
  • 31.Arruda E, Boyle TR, Winther B. Localization of human rhinovirus replication in the upper respiratory tract by in situ hybridization. J Infect Dis. 1995;171:1329–1333. doi: 10.1093/infdis/171.5.1329. [DOI] [PubMed] [Google Scholar]
  • 32.Turner RB, Hendley JO, Gwaltney JM., Jr Shedding of infected ciliated epithelial cells in rhinovirus colds. J Infect Dis. 1982;145:849–853. doi: 10.1093/infdis/145.6.849. [DOI] [PubMed] [Google Scholar]
  • 33.Gwaltney JM, Jr, Phillips CD, Miller RD, Riker DK. Computed tomographic study of the common cold. N Engl J Med. 1994;330:25–30. doi: 10.1056/NEJM199401063300105. [DOI] [PubMed] [Google Scholar]
  • 34.Turner RB. Elaboration of interleukin 8 from fibroblast cells and human nasal epithelium in response to rhinovirus challenge [Abstract B43]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, FL. Am Soc Microbiol. 1994;65 [Google Scholar]
  • 35.Halperin SA, Eggleston PA, Hendley JO. Pathogenesis of lower respiratory tract symptoms in experimental rhinovirus infection. Am Rev Respir Dis. 1983;128:806–810. doi: 10.1164/arrd.1983.128.5.806. [DOI] [PubMed] [Google Scholar]
  • 36.Calhoun WJ, Dick EC, Schwartz LB, Busse WW. A common cold virus, rhinovirus 16, potentiates airway inflammation after segmental antigen bronchoprovocation in allergic subjects. J Clin Invest. 1994;94:2200–2208. doi: 10.1172/JCI117581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Douglas RG., Jr Pathogenesis of rhinovirus common colds in human volunteers. Ann Otol Rhinol Laryngol. 1970;79:563–571. doi: 10.1177/000348947007900320. [DOI] [PubMed] [Google Scholar]
  • 38.Igarashi Y, Skoner DP, Doyle WJ. Analysis of nasal secretions during experimental rhinovirus upper respiratory infections. J Allergy Clin Immunol. 1993;92:722–731. doi: 10.1016/0091-6749(93)90016-9. [DOI] [PubMed] [Google Scholar]
  • 39.Winther B, Farr B, Turner RB. Histopathologic examination and enumeration of polymorphonuclear leukocytes in the nasal mucosa during experimental rhinovirus colds. Acta Otolaryngol (Stockh) 1984:19–24. doi: 10.3109/00016488409128537. [DOI] [PubMed] [Google Scholar]
  • 40.Winther B, Brofeldt S, Christensen B, Mygind N. Light and scanning electron microscopy of nasal biopsy material from patients with naturally acquired common colds. Acta Otolaryngol (Stockh) 1984;97:309–318. doi: 10.3109/00016488409130994. [DOI] [PubMed] [Google Scholar]
  • 41.Winther B, Gwaltney JM, Jr, Hendley JO. Respiratory virus infection of monolayer cultures of human nasal epithelial cells. Am Rev Respir Dis. 1990;141:839–845. doi: 10.1164/ajrccm/141.4_Pt_1.839. [DOI] [PubMed] [Google Scholar]
  • 42.Cate TR, Couch RB, Johnson KM. Studies with rhinovirus in volunteers: Production of illness, effect of naturally acquired antibody, and demonstration of a protective effect not associated with serum antibody. J Clin Invest. 1964;43:56–67. doi: 10.1172/JCI104894. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Cate TR, Rossen RD, Douglas R., Jr The role of nasal secretion and serum antibody in the rhinovirus common cold. Am J Epidemiol. 1966;84:352–363. doi: 10.1093/oxfordjournals.aje.a120648. [DOI] [PubMed] [Google Scholar]
  • 44.Rossen RD, Kasel JA, Couch RB. The secretory immune system: Its relation to respiratory viral infection. Prog Med Virol. 1971;13:194–238. [Google Scholar]
  • 45.Perkins JC, Tucker DN, Knopf HL. Comparison of protective effect of neutralizing antibody in serum and nasal secretions in experimental rhinovirus type 13 illness. Am J Epidemiol. 1969;90:519–526. doi: 10.1093/oxfordjournals.aje.a121098. [DOI] [PubMed] [Google Scholar]
  • 46.Barclay WS, Al-Nakib W. An ELISA for the detection of rhinovirus specific antibody in serum and nasal secretions. J Virol Methods. 1987;15:53–64. doi: 10.1016/0166-0934(87)90048-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Douglas RG, Jr, Alford RH, Cate TR, Couch RB. The leukocyte response during viral respiratory illness in man. Ann Intern Med. 1966;64:521–530. doi: 10.7326/0003-4819-64-3-521. [DOI] [PubMed] [Google Scholar]
  • 48.Naclerio RM, Proud D, Lichtenstein LM. Kinins are generated during experimental rhinovirus colds. J Infect Dis. 1988;157:133–142. doi: 10.1093/infdis/157.1.133. [DOI] [PubMed] [Google Scholar]
  • 49.Levandowski RA, Ou DW, Jackson GG. Acute-phase decrease of T lymphocyte subsets in rhinovirus infection. J Infect Dis. 1986;153:743–748. doi: 10.1093/infdis/153.4.743. [DOI] [PubMed] [Google Scholar]
  • 50.Skoner DP, Whiteside TL, Wilson JW. Effect of rhinovirus 39 infection on cellular immune parameters in allergic and nonallergic subjects. J Allergy Clin Immunol. 1993;92:732–743. doi: 10.1016/0091-6749(93)90017-a. [DOI] [PubMed] [Google Scholar]
  • 51.Winther B. Effects on the nasal mucosa of upper respiratory viruses (common cold) Dan Med Bull. 1994;41:193–204. [PubMed] [Google Scholar]
  • 52.Levandowski RA, Weaver CW, Jackson GG. Nasal-secretion leukocyte populations determined by flow cytometry during acute rhinovirus infection. J Med Virol. 1988;25:423–432. doi: 10.1002/jmv.1890250406. [DOI] [PubMed] [Google Scholar]
  • 53.Eggleston PA, Hendley JO, Gwaltney JM., Jr Histamine in nasal secretions. Int Arch Allergy Appl Immunol. 1978;57:193–200. doi: 10.1159/000232103. [DOI] [PubMed] [Google Scholar]
  • 54.Eggleston PA, Hendley JO, Gwaltney JM., Jr Mediators of immediate hypersensitivity in nasal secretions during natural colds and rhinovirus infection. Acta Otolaryngol Suppl. 1984;413:25–35. doi: 10.3109/00016488409128538. [DOI] [PubMed] [Google Scholar]
  • 55.Proud D, Naclerio RM, Gwaltney JM, Jr, Hendley JO. Kinins are generated in nasal secretions during natural rhinovirus colds. J Infect Dis. 1990;161:120–123. doi: 10.1093/infdis/161.1.120. [DOI] [PubMed] [Google Scholar]
  • 56.Proud D, Reynolds CJ, LaCapra S. Nasal provocation with bradykinin induces symptoms of rhinitis and a sore throat. Am Rev Respir Dis. 1988;137:613–616. doi: 10.1164/ajrccm/137.3.613. [DOI] [PubMed] [Google Scholar]
  • 57.Higgins PG, Barrow GI, Tyrrell DA. A study of the efficacy of the bradykinin antagonist, NPC 567, in rhinovirus infections in human volunteers. Antiviral Res. 1990;14:339–344. doi: 10.1016/0166-3542(90)90052-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Gustafson M, Proud D, Hendley JO. Oral prednisone therapy in experimental rhinovirus infections. J Allergy Clin Immunol. 1996;97:1009–1014. doi: 10.1016/s0091-6749(96)80077-7. [DOI] [PubMed] [Google Scholar]
  • 59.Proud D, Gwaltney JM, Jr, Hendley JO. Increased levels of interleukin-1 are detected in nasal secretions of volunteers during experimental rhinovirus colds. J Infect Dis. 1994;169:1007–1013. doi: 10.1093/infdis/169.5.1007. [DOI] [PubMed] [Google Scholar]
  • 60.Zhu Z, Tang W, Ray A. Rhinovirus stimulation of interleukin-6 in vivo and in vitro: evidence for nuclear factor kB-dependent transcriptional activation. J Clin Invest. 1996;97:421–430. doi: 10.1172/JCI118431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Turner RB, Weingand K, Yeh CH. Association between interleukin-8 (IL-8) and symptom severity in rhinovirus colds [Abstract H48]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, Am Soc Microbiol. 1996:171. [Google Scholar]
  • 62.Douglas JA, Dhami D, Gurr CE. Influence of interleukin-8 challenge in the nasal mucosa in atopic and nonatopic subjects. Am J Respir Crit Care Med. 1994;150:1108–1113. doi: 10.1164/ajrccm.150.4.7921444. [DOI] [PubMed] [Google Scholar]
  • 63.Aquilina AT, Hall WJ, Douglas RG, Jr, Utell MJ. Airway reactivity in subjects with viral upper respiratory tract infections: the effects of exercise and cold air. Am Rev Respir Dis. 1980;122:3–10. doi: 10.1164/arrd.1980.122.1.3. [DOI] [PubMed] [Google Scholar]
  • 64.Empey DW, Laitinen LA, Jacobs L. Mechanisms of bronchial hyperreactivity in normal subjects after upper respiratory infection. Am Rev Respir Dis. 1976;113:131–139. doi: 10.1164/arrd.1976.113.2.131. [DOI] [PubMed] [Google Scholar]
  • 65.Zerial A, Werner GH, Phillpotts RJ. Studies on 44 081 R.P., a new antirhinovirus compound, in cell cultures and in volunteers. Antimicrob Agents Chemother. 1985;27:846–850. doi: 10.1128/aac.27.5.846. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Woods MG, Diana GD, Rogge MC. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother. 1989;33:2069–2074. doi: 10.1128/aac.33.12.2069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Rozhon E, Cox S, Buontempo P. SCH 38057: a picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating. Antiviral Res. 1993;21:15–35. doi: 10.1016/0166-3542(93)90064-p. [DOI] [PubMed] [Google Scholar]
  • 68.Kenny MT, Dulworth JK, Torney HL. In vitro and in vivo antipicornavirus activity of some phenoxypyridinecarbonitriles. Antimicrob Agents Chemother. 1985;28:745–750. doi: 10.1128/aac.28.6.745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Ishitsuka H, Ninomiya YT, Ohsawa C. Direct and specific inactivation of rhinovirus by chalcone Ro 09-0410. Antimicrob Agents Chemother. 1982;22:617–621. doi: 10.1128/aac.22.4.617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.DeLong DC, Reed SE. Inhibition of rhinovirus replication in organ culture by a potential antiviral drug. J Infect Dis. 1980;141:87–91. doi: 10.1093/infdis/141.1.87. [DOI] [PubMed] [Google Scholar]
  • 71.Came PE, Schafer TW, Silver GH. Sensitivity of rhinoviruses to human leukocyte and fibroblast interferons. J Infect Dis. 1976;133(Suppl):A136–A139. doi: 10.1093/infdis/133.supplement_2.a136. [DOI] [PubMed] [Google Scholar]
  • 72.Andries K, Dewindt B, Snoeks J. In vitro activity of Pirodavir (R 77975), a substituted phenoxypyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob Agents Chemother. 1992;36:100–107. doi: 10.1128/aac.36.1.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Abraham G, Colonno RJ. Many rhinovirus serotypes share the same cellular receptor. J Virol. 1984;51:340–345. doi: 10.1128/jvi.51.2.340-345.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Colonno RJ, Callahan PL, Long WJ. Isolation of a monoclonal antibody that blocks attachment of the major group of human rhinoviruses. J Virol. 1986;57:7–12. doi: 10.1128/jvi.57.1.7-12.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Greve JM, Davis G, Meyer AM. The major human rhinovirus receptor is ICAM-1. Cell. 1989;56:839–847. doi: 10.1016/0092-8674(89)90688-0. [DOI] [PubMed] [Google Scholar]
  • 76.Staunton DE, Merluzzi VJ, Rothlein R. A cell adhesion molecule, ICAM-1 is the major surface receptor for rhinoviruses. Cell. 1989;56:849–853. doi: 10.1016/0092-8674(89)90689-2. [DOI] [PubMed] [Google Scholar]
  • 77.Marlin SD, Staunton DE, Springer TA. A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection. Nature. 1990;344:70–72. doi: 10.1038/344070a0. [DOI] [PubMed] [Google Scholar]
  • 78.Crump CE, Arruda E, Hayden FG. In vitro inhibitory activity of soluble ICAM-1 for the numbered serotypes of human rhinovirus. Antiviral Chem Chemother. 1993;4:323–327. [Google Scholar]
  • 79.Condra JH, Sardana VV, Tomassini JE. Bacterial expression of antibody fragments that block human rhinovirus infection of cultured cells. J Biol Chem. 1990;265:2292–2295. [PubMed] [Google Scholar]
  • 80.de Arruda E, Crump CE, Marlin SD. In vitro studies of the antirhino-virus activity of soluble intercellular adhesion molecule-1. Antimicrob Agents Chemother. 1992;36:1186–1191. doi: 10.1128/aac.36.6.1186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Korant BD, Kauer JC, Butterworth BE. Zinc ions inhibit replication of rhinoviruses. Nature (London) 1974;248:588–590. doi: 10.1038/248588a0. [DOI] [PubMed] [Google Scholar]
  • 82.Al-Nakib W, Higgins PG, Barrow I. Prophylaxis and treatment of rhinovirus colds with zinc gluconate lozenges. J Antimicrob Chemother. 1987;20:893–901. doi: 10.1093/jac/20.6.893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Farr BM, Conner EM, Betts RF. Two randomized controlled trials of zinc gluconate lozenge therapy of experimentally induced rhinovirus colds. Antimicrob Agents Chemother. 1987;31:1183–1187. doi: 10.1128/aac.31.8.1183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Smith DS, Helzner EC, Nuttall CE., Jr Failure of zinc gluconate in treatment of acute upper respiratory tract infections. Antimicrob Agents Chemother. 1989;33:646–648. doi: 10.1128/aac.33.5.646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Mossad SB, Macknin ML, Medendorp SV, Mason P. Zinc gluconate lozenges for treating the common cold: a randomized, double-blind, placebo-controlled study. Ann Intern Med. 1996;125:81–88. doi: 10.7326/0003-4819-125-2-199607150-00001. [DOI] [PubMed] [Google Scholar]
  • 86.Eby GA, Davis DR, Halcomb WW. Reduction in duration of common colds by zinc gluconate lozenges in a double-blind study. Antimicrob Agents Chemother. 1984;25:20–24. doi: 10.1128/aac.25.1.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Smith MBH, Feldman W. Over-the-counter cold medications. A critical review of clinical trials between 1950 and 1991. JAMA. 1993;269:2258–2263. doi: 10.1001/jama.269.17.2258. [DOI] [PubMed] [Google Scholar]
  • 88.Akerlund A, Klint T, Olen L, Rundcrantz H. Nasal decongestant effect of oxymetazoline in the common cold: a objective dose-response study in 106 patients. J Laryngol Otol. 1989;103:743–746. doi: 10.1017/s0022215100109958. [DOI] [PubMed] [Google Scholar]
  • 89.Doyle WJ, Riker DK, McBride TP. Therapeutic effects of an anticholinergic-sympathomimetic combination in induced rhinovirus colds. Ann Otol Rhinol Laryngol. 1993;102:521–527. doi: 10.1177/000348949310200706. [DOI] [PubMed] [Google Scholar]
  • 90.Sperber SJ, Sorrentino JV, Riker DK, Hayden FG. Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bull N Y Acad Med. 1989;65:145–160. [PMC free article] [PubMed] [Google Scholar]
  • 91.Connell JT, Linzmayer MI. Comparison of nasal airway patency changes after treatment with oxymetazoline and pseudoephedrine. Am J Rhinol. 1987;1:87–94. [Google Scholar]
  • 92.Gaffey MJ, Gwaltney JM, Jr, Dressler WE. Intranasally ad ministered atropine methonitrate treatment of experimental rhinovirus colds. Am Rev Respir Dis. 1987;135:241–244. doi: 10.1164/arrd.1987.135.1.241. [DOI] [PubMed] [Google Scholar]
  • 93.Gaffey MJ, Hayden FG, Boyd JC, Gwaltney JM., Jr Ipratropium bromide treatment of experimental rhinovirus secretion. Antimicrob Agents Chemother. 1988;32:1644–1647. doi: 10.1128/aac.32.11.1644. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Duckhorn R, Grossman J, Posner M. A double-blind, placebo-controlled study of the safety and efficacy of ipratropium bromide nasal spray versus placebo in patients with the common cold. J Allergy Clin Immunol. 1992;90:1076–1082. doi: 10.1016/0091-6749(92)90126-m. [DOI] [PubMed] [Google Scholar]
  • 95.Diamond L, Dockhorn RJ, Grossman J. A dose-response study of the efficacy and safety of ipratropium bromide nasal spray in the treatment of the common cold. J Allergy Clin Immunol. 1995;95:1139–1146. doi: 10.1016/s0091-6749(95)70219-9. [DOI] [PubMed] [Google Scholar]
  • 96.Hayden FG, Diamond L, Wood PB. Effectiveness and safety of intranasal ipratropium bromide in common colds: a randomized, doubleblind, placebo-controlled trial. Ann Intern Med. 1996;125:89–97. doi: 10.7326/0003-4819-125-2-199607150-00002. [DOI] [PubMed] [Google Scholar]
  • 97.Sakchainanont B, Chantarojanasiri T, Ruangkanchanasetr S. Effectiveness of antihistamines in common cold. J Med Assoc Thai. 1990;73:96–101. [PubMed] [Google Scholar]
  • 98.Howard JC, Jr, Kantner TR, Lilienfield LS. Effectiveness of antihistamines in the symptomatic management of the common cold. JAMA. 1979;242:2414–2417. [PubMed] [Google Scholar]
  • 99.Gaffey MJ, Gwaltney JM, Jr, Sastre A. Intranasally and orally administered antihistamine treatment of experimental rhinovirus colds. Am Rev Respir Dis. 1987;136:556–560. doi: 10.1164/ajrccm/136.3.556. [DOI] [PubMed] [Google Scholar]
  • 100.Doyle WJ, McBride TP, Skoner DP. A double-blind, placebo-controlled clinical trial of the effect of chlorpheniramine on the response of the nasal airway, middle ear and eustachian tube to provocative rhinovirus challenge. Pediatr Infect Dis J. 1988;7:229–238. doi: 10.1097/00006454-198803000-00033. [DOI] [PubMed] [Google Scholar]
  • 101.Gwaltney JM, Jr, Park J, Paul RA. Randomized controlled trial of clemastine fumarate for treatment of experimental rhinovirus colds. Clin Infect Dis. 1996;22:656–662. doi: 10.1093/clinids/22.4.656. [DOI] [PubMed] [Google Scholar]
  • 102.Turner RB, Sperber SJ, Sorrentino JV, et al. Effectiveness of clemastine fumarate for treatment of rhinorrhea and sneezing associated with the common cold. Clin Infect Dis (in press). [DOI] [PubMed]
  • 103.Gaffey MJ, Kaiser DL, Hayden FG. Ineffectiveness of oral terfenadine in natural colds: evidence against histamine as a mediator of common cold symptoms. Pediatr Infect Dis J. 1988;7:223–228. doi: 10.1097/00006454-198803000-00032. [DOI] [PubMed] [Google Scholar]
  • 104.Berkowitz RB, Tinkelman DG. Evaluation of oral terfenadine for treatment of the common cold. Ann Allergy. 1991;67:593–597. [PubMed] [Google Scholar]
  • 105.Curley FJ, Irwin RS, Pratter MR. Cough and the common cold. Am Rev Respir Dis. 1988;138:305–311. doi: 10.1164/ajrccm/138.2.305. [DOI] [PubMed] [Google Scholar]
  • 106.Wald ER, Reilly JS, Casselbrant M. Treatment of acute maxillary sinusitis in childhood: a comparative study of amoxicillin and cefaclor. J Pediatr. 1984;104:297–302. doi: 10.1016/s0022-3476(84)81018-5. [DOI] [PubMed] [Google Scholar]
  • 107.Korppi M, Laurikainen K, Pietikainen M, Silvasti M. Antitussives in the treatment of acute transient cough in children. Acta Paediatr Scand. 1991;80:969–971. doi: 10.1111/j.1651-2227.1991.tb11764.x. [DOI] [PubMed] [Google Scholar]
  • 108.Tukiainen H, Karttunen P, Silvasti M. The treatment of acute transient cough: a placebo-controlled comparison of dextromethorphan and dextromethorphan-beta2-sympathomimetic combination. Eur J Respir Dis. 1986;69:95–99. [PubMed] [Google Scholar]
  • 109.Sperber SJ, Hendley JO, Hayden FG. Effects of naproxen on experimental rhinovirus colds. A randomized, double-blind, controlled trial. Ann Intern Med. 1992;117:37–41. doi: 10.7326/0003-4819-117-1-37. [DOI] [PubMed] [Google Scholar]
  • 110.Kuhn JJ, Hendley JO, Adams KF. Antitussive effect of guaifenesin in young adults with natural colds. Objective and subjective assessment. Chest. 1982;82:713–718. doi: 10.1378/chest.82.6.713. [DOI] [PubMed] [Google Scholar]
  • 111.Gwaltney JM., Jr Combined antiviral and antimediator treatment of rhinovirus colds. J Infect Dis. 1992;166:776–782. doi: 10.1093/infdis/166.4.776. [DOI] [PubMed] [Google Scholar]
  • 112.Sattar SA, Jacobsen H, Springthorpe VS. Chemical disinfection to interrupt transfer of rhinovirus type 14 from environmental surfaces to hands. Appl Environ Microbiol. 1993;59:1579–1585. doi: 10.1128/aem.59.5.1579-1585.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Hendley JO, Mika LA, Gwaltney JM., Jr Evaluation of virucidal compounds for inactivation of rhinovirus on hands. Antimicrob Agents Chemother. 1978;14:690–694. doi: 10.1128/aac.14.5.690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114.Hayden GF, DeForest D, Hendley JO, Gwaltney JM., Jr Inactivation of rhinovirus on human fingers by virucidal activity of glutaric acid. Antimicrob Agents Chemother. 1984;26:928–929. doi: 10.1128/aac.26.6.928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115.Dick EC, Hossain SU, Mink KA. Interruption of transmission of rhinovirus colds among human volunteers using virucidal paper handkerchiefs. J Infect Dis. 1986;153:352–356. doi: 10.1093/infdis/153.2.352. [DOI] [PubMed] [Google Scholar]
  • 116.Hayden GF, Hendley JO, Gwaltney JM., Jr The effect of placebo and virucidal paper handkerchiefs on viral contamination of the hand and transmission of experimental rhinoviral infection. J Infect Dis. 1985;152:403–407. doi: 10.1093/infdis/152.2.403. [DOI] [PubMed] [Google Scholar]
  • 117.Hayden GF, Gwaltney JM, Jr, Thacker DF, Hendley JO. Rhinovirus inactivation by nasal tissues treated with virucide. Antiviral Res. 1985;5:103–109. doi: 10.1016/0166-3542(85)90036-1. [DOI] [PubMed] [Google Scholar]
  • 118.Hayden FG, Gwaltney JM, Jr, Colonno RJ. Modification of experimental rhinovirus colds by receptor blockade. Antiviral Res. 1988;9:233–247. doi: 10.1016/0166-3542(88)90055-1. [DOI] [PubMed] [Google Scholar]
  • 119.Barrow GI, Higgins PG, Tyrrell DAJ, Andries K. An appraisal of the efficacy of the antiviral R 61837 in rhinovirus infections in human volunteers. Antiviral Chem Chemother. 1990;1:279–283. [Google Scholar]
  • 120.Hayden FG, Andries K, Janssen PA. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob Agents Chemother. 1992;36:727–732. doi: 10.1128/aac.36.4.727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Douglas RM, Moore BW, Miles HB. Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting. N Engl J Med. 1986;314:65–70. doi: 10.1056/NEJM198601093140201. [DOI] [PubMed] [Google Scholar]
  • 122.Hayden FG, Gwaltney JM., Jr Intranasal interferon alpha 2 for prevention of rhinovirus infection and illness. J Infect Dis. 1983;148:543–550. doi: 10.1093/infdis/148.3.543. [DOI] [PubMed] [Google Scholar]
  • 123.Hayden FG, Gwaltney JM., Jr Intranasal interferon-alpha2 treatment of experimental rhinovirus colds. J Infect Dis. 1984;150:174–180. doi: 10.1093/infdis/150.2.174. [DOI] [PubMed] [Google Scholar]
  • 124.Hayden FG, Albrecht JK, Kaiser DL, Gwaltney JM., Jr Prevention of natural colds by contact prophylaxis with intranasal alpha2-interferon. N Engl J Med. 1986;314:71–75. doi: 10.1056/NEJM198601093140202. [DOI] [PubMed] [Google Scholar]
  • 125.Higgins PG, Al-Nakib W, Willman J, Tyrrell DA. Interferon-beta ser as prophylaxis against experimental rhinovirus infection in volunteers. J Interferon Res. 1986;6:153–159. doi: 10.1089/jir.1986.6.153. [DOI] [PubMed] [Google Scholar]
  • 126.Monto AS, Shope TC, Schwartz SA, Albrecht JK. Intranasal interferon-a2b for seasonal prophylaxis of respiratory infection. J Infect Dis. 1986;154:128–133. doi: 10.1093/infdis/154.1.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127.Hayden FG, Mills SE, Johns ME. Human tolerance and histopathologic effects of long-term administration of intranasal interferon-α2. J Infect Dis. 1983;148:914–921. doi: 10.1093/infdis/148.5.914. [DOI] [PubMed] [Google Scholar]
  • 128.Samo TC, Greenberg SB, Couch RB. Efficacy and tolerance of intranasally applied recombinant leukocyte A interferon in normal volunteers. J Infect Dis. 1983;148:535–542. doi: 10.1093/infdis/148.3.535. [DOI] [PubMed] [Google Scholar]
  • 129.Samo TC, Greenberg SB, Palmer JM. Intranasally applied recombinant leukocyte A interferon in normal volunteers. II. Determination of minimal effective and tolerable dose. J Infect Dis. 1984;150:181–188. doi: 10.1093/infdis/150.2.181. [DOI] [PubMed] [Google Scholar]
  • 130.Scott GM, Onwubalili JK, Robinson JA. Tolerance of one-month intranasal interferon. J Med Virol. 1985;17:99–106. doi: 10.1002/jmv.1890170202. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of Allergy, Asthma & Immunology are provided here courtesy of Elsevier

RESOURCES